Management of chronic hepatitis B;Prise en charge de l'hépatite B chronique: Un défi en évolution constante

Revue Medicale Suisse

Volumn 6, Issue 233, 2010, Pages 168-173

  Doerig, Christopher ^a   Antonino, Anca ^a   Pache, Isabelle ^a   Moradpour, Darius ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN; INFLIXIMAB; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; SEROCONVERSION; VACCINATION; VIROLOGY; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS;

EID: 76749084855     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
2. Lok ASF, McMahon BJ. AASLD practice guidelines: chronic hepatitis B: Update 2009. Hepatology 2009; 50:1-36.
3. * EASL clinical practice guideline: Management of chronic hepatitis B. J Hepatol 2009;50:227-42.
4. * Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
5. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-51.
6. Zoulim F, Perrillo R. Hepatitis B: Reflections on the current approach to antiviral therapy. J Hepatol 2008; 48(Suppl. 1):S2-19.
7. Doerig C, Sahli R, Telenti A, et al. Prévention et prise en charge de la résistance antivirale dans l'hépatite B chronique. Rev Med Suisse 2009;5:203-8.
8. * Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleotide analogues. Gastroenterology 2009;137:1593-608.
9. * Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7.
10. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-40.
11. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712.
12. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(Suppl. 1):S156-S65.
13. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8.